News

AbstractRenin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may…

AbstractSickle cell disease (SCD) is a globally prevalent inherited hemoglobinopathy marked by chronic hemolysis, vaso-occlusion, and systemic inflammation, leading…

― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global…

AbstractAlloimmunisation is a notorious dilemma in blood transfusion intervention therapy, especially in low-resource countries, and studies have shown that…

AbstractSickle cell disease (SCD) is a major global health burden, and early, accurate diagnosis is critical for effective management. Conventional diagnostic…

Health Minister Y. Satya Kumar on Friday said that the State government is committed to strengthening healthcare infrastructure and improving medical services in…

Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding…

AbstractThe Cure Sickle Cell Initiative (CureSCi), created by the National Heart, Lung, and Blood Institute, has developed data standards to increase…

SummarySickle cell disease (SCD) is a complex thrombo-inflammatory disorder in which haemolysis, platelet activation, thrombocytosis, inflammation and endothelial…

AbstractBackground: Sickle cell anemia (SCA) is a genetic disease marked by abnormal hemoglobin S and sickle-shaped red blood cells. It is highly prevalent in sub-…